Literature DB >> 19513633

Large scale production of stem cells and their derivatives.

Robert Zweigerdt1.   

Abstract

Stem cells have been envisioned to become an unlimited cell source for regenerative medicine. Notably, the interest in stem cells lies beyond direct therapeutic applications. They might also provide a previously unavailable source of valuable human cell types for screening platforms, which might facilitate the development of more efficient and safer drugs. The heterogeneity of stem cell types as well as the numerous areas of application suggests that differential processes are mandatory for their in vitro culture. Many of the envisioned applications would require the production of a high number of stem cells and their derivatives in scalable, well-defined and potentially clinical compliant manner under current good manufacturing practice (cGMP). In this review we provide an overview on recent strategies to develop bioprocesses for the expansion, differentiation and enrichment of stem cells and their progenies, presenting examples for adult and embryonic stem cells alike.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513633     DOI: 10.1007/10_2008_27

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  30 in total

1.  Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors.

Authors:  Ruth Olmer; Andreas Lange; Sebastian Selzer; Cornelia Kasper; Axel Haverich; Ulrich Martin; Robert Zweigerdt
Journal:  Tissue Eng Part C Methods       Date:  2012-06-04       Impact factor: 3.056

2.  A novel miniaturized multimodal bioreactor for continuous in situ assessment of bioartificial cardiac tissue during stimulation and maturation.

Authors:  George Kensah; Ina Gruh; Jörg Viering; Henning Schumann; Julia Dahlmann; Heiko Meyer; David Skvorc; Antonia Bär; Payam Akhyari; Alexander Heisterkamp; Axel Haverich; Ulrich Martin
Journal:  Tissue Eng Part C Methods       Date:  2011-01-14       Impact factor: 3.056

3.  Cardiac differentiation of human pluripotent stem cells in scalable suspension culture.

Authors:  Henning Kempf; Christina Kropp; Ruth Olmer; Ulrich Martin; Robert Zweigerdt
Journal:  Nat Protoc       Date:  2015-08-13       Impact factor: 13.491

4.  A lower volume culture method for obtaining a larger yield of neuron-like cells from mesenchymal stem cells.

Authors:  Atsushi Shimomura; Akiko Iizuka-Kogo; Naoki Yamamoto; Ryuji Nomura
Journal:  Med Mol Morphol       Date:  2015-12-23       Impact factor: 2.309

5.  Scalable expansion of human pluripotent stem cells in suspension culture.

Authors:  Robert Zweigerdt; Ruth Olmer; Harmeet Singh; Axel Haverich; Ulrich Martin
Journal:  Nat Protoc       Date:  2011-04-28       Impact factor: 13.491

6.  Online- and offline- monitoring of stem cell expansion on microcarrier.

Authors:  C Justice; J Leber; D Freimark; P Pino Grace; M Kraume; P Czermak
Journal:  Cytotechnology       Date:  2011-05-12       Impact factor: 2.058

7.  Scalable 96-well Plate Based iPSC Culture and Production Using a Robotic Liquid Handling System.

Authors:  Michael K Conway; Michael J Gerger; Erin E Balay; Rachel O'Connell; Seth Hanson; Neil J Daily; Tetsuro Wakatsuki
Journal:  J Vis Exp       Date:  2015-05-14       Impact factor: 1.355

8.  Suspension Culture of Human Induced Pluripotent Stem Cells in Single-Use Vertical-Wheel™ Bioreactors Using Aggregate and Microcarrier Culture Systems.

Authors:  Diogo E S Nogueira; Carlos A V Rodrigues; Yas Hashimura; Sunghoon Jung; Brian Lee; Joaquim M S Cabral
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Stem Cell Spheroids and Ex Vivo Niche Modeling: Rationalization and Scaling-Up.

Authors:  Isotta Chimenti; Diana Massai; Umberto Morbiducci; Antonio Paolo Beltrami; Maurizio Pesce; Elisa Messina
Journal:  J Cardiovasc Transl Res       Date:  2017-03-13       Impact factor: 4.132

Review 10.  Concise review: cell therapies: the route to widespread adoption.

Authors:  Lucy Foley; Michael Whitaker
Journal:  Stem Cells Transl Med       Date:  2012-05-09       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.